KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Ionis Pharmaceuticals (IONS) Revenue (2016 - 2025)

Historic Revenue for Ionis Pharmaceuticals (IONS) over the last 17 years, with Q3 2025 value amounting to $156.7 million.

  • Ionis Pharmaceuticals' Revenue rose 1711.7% to $156.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $792.9 million, marking a year-over-year decrease of 126.49%. This contributed to the annual value of $705.1 million for FY2024, which is 1047.54% down from last year.
  • Per Ionis Pharmaceuticals' latest filing, its Revenue stood at $156.7 million for Q3 2025, which was up 1711.7% from $278.0 million recorded in Q2 2025.
  • In the past 5 years, Ionis Pharmaceuticals' Revenue ranged from a high of $440.0 million in Q4 2021 and a low of $111.6 million during Q1 2021
  • Moreover, its 5-year median value for Revenue was $144.2 million (2023), whereas its average is $181.9 million.
  • In the last 5 years, Ionis Pharmaceuticals' Revenue surged by 96797.57% in 2021 and then crashed by 6548.0% in 2022.
  • Ionis Pharmaceuticals' Revenue (Quarter) stood at $440.0 million in 2021, then crashed by 65.48% to $151.9 million in 2022, then skyrocketed by 113.64% to $324.5 million in 2023, then plummeted by 30.18% to $226.6 million in 2024, then crashed by 30.83% to $156.7 million in 2025.
  • Its Revenue stands at $156.7 million for Q3 2025, versus $278.0 million for Q2 2025 and $131.6 million for Q1 2025.